Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02879695
Title Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: senior | adult | child
Covered Countries USA

Facility Status City State Zip Country Details
Yale University New Haven Connecticut 06520 United States Details
University of Kentucky/Markey Cancer Center Lexington Kentucky 40536 United States Details
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore Maryland 21287 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh Pennsylvania 15232 United States Details
Huntsman Cancer Institute/University of Utah Salt Lake City Utah 84112 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field